A peptide pulled from amphibian skin slowed the signs of vascular aging in old mice, and a single enzyme inside the cell appears to explain why.
The peptide, called AL-VI10, is described in a study published May 18 in Zoological Research ↗. It is short, made by an animal's own skin, and as far as the authors can find, the first amphibian-derived peptide shown to act on the aging of blood vessels. The interesting part is not that a peptide mopped up free radicals. Plenty of molecules do. It is that knocking out one enzyme erased the benefit, which turns a vague antioxidant story into a specific, testable pathway.
What the peptide did
The team aged mice on the cheap, using D-galactose, a sugar that when injected daily speeds up aging-like damage and is a standard lab shortcut for studying it. In those animals, AL-VI10 reduced the thickening of the middle layer of the artery wall, a structural change that stiffens vessels as they age. It lowered inflammatory signals and cut levels of matrix metalloproteinases, enzymes that chew up the scaffold that holds a vessel together. It also pushed autophagy, the cell's own recycling and self-cleaning process, back up.
Then the group moved to human cells. They took endothelial cells, the single layer that lines the inside of every blood vessel, and forced them into senescence (a worn-out, no-longer-dividing state) with hydrogen peroxide. AL-VI10 lowered the standard flags of that state, including the senescence stain SA-beta-gal and the arrest proteins p53 and p21. The treated cells started dividing and migrating again, and they made more eNOS, the enzyme that produces nitric oxide, the molecule that lets a vessel relax and widen. Stiff, non-relaxing vessels are a large part of what goes wrong with cardiovascular aging, so getting eNOS back up is the readout that matters most here.
The one enzyme that mattered
The mechanism is where the paper earns its claim. AL-VI10 raised two proteins, SIRT1 and Nrf2, both well-known hubs in stress resistance and aging biology. SIRT1 is a sensor that helps cells cope with metabolic and oxidative stress; Nrf2 is the master switch for a cell's antioxidant defenses. When the researchers blocked SIRT1 with a drug, the Nrf2 boost disappeared and the protective effect weakened. That ordering matters. It means SIRT1 sits upstream, acting as a gate: the peptide works through it, not around it. An antioxidant that works through a named, blockable switch is a drug lead. An antioxidant that just lowers a damage number is a supplement.
What the study does not have is just as important. There are no human data, no exact effect sizes in the public abstract, and no disclosed sequence. D-galactose mice age fast in a dish-like, artificial way that does not capture decades of real vascular wear. The list of molecules that reversed aging in a mouse and then did nothing in people is long, and "anti-aging peptide" is one of the easiest claims to make and hardest to land. Read this as a clean mechanism in a model, not a therapy.
Where it sits on the map
Peptides that act on aging are a real and growing class, and peptidemodel tracks them under longevity ↗. The body's own entries there, like MOTS-c ↗ and Humanin ↗, work mostly through the mitochondria ↗, the cell's power plants. AL-VI10 comes in from a different door, the SIRT1 and Nrf2 antioxidant axis, and from an unusual source, amphibian skin, which has already given drug hunters a long list of antimicrobial and wound-healing peptides. It does not have a card on the platform yet; there is no published sequence to build one from. If the group releases the sequence and the SIRT1-gated mechanism holds up in a real aging model, it would be a candidate worth one.